Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$221.06-0.7%$237.59$146.12▼$251.71$532.24B0.278.42 million shs1.53 million shsNVAXNovavax$10.44+13.1%$9.05$5.80▼$11.97$1.72B2.374.82 million shs8.32 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson-0.93%-3.38%-6.75%-7.46%+41.43%NVAXNovavax-1.39%+16.39%+15.66%+11.88%+55.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$221.06-0.7%$237.59$146.12▼$251.71$532.24B0.278.42 million shs1.53 million shsNVAXNovavax$10.44+13.1%$9.05$5.80▼$11.97$1.72B2.374.82 million shs8.32 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson-0.93%-3.38%-6.75%-7.46%+41.43%NVAXNovavax-1.39%+16.39%+15.66%+11.88%+55.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.67Moderate Buy$252.4814.21% UpsideNVAXNovavax 2.20Hold$12.1316.13% UpsideCurrent Analyst Ratings BreakdownLatest NVAX and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026NVAXNovavax TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$8.00 ➝ $9.004/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B+) ➝ Buy (B)4/20/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$244.00 ➝ $266.004/16/2026JNJJohnson & Johnson ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$240.00 ➝ $275.004/16/2026JNJJohnson & Johnson Daiwa Securities GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$237.00 ➝ $246.004/15/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$283.004/15/2026JNJJohnson & Johnson Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$265.004/15/2026JNJJohnson & Johnson Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$220.00 ➝ $250.004/15/2026JNJJohnson & Johnson BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$234.00 ➝ $255.004/15/2026JNJJohnson & Johnson Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$253.00 ➝ $254.004/15/2026JNJJohnson & Johnson Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$237.00 ➝ $258.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$94.19B5.65$13.89 per share15.91$33.73 per share6.55NVAXNovavax$1.12B1.53$3.91 per share2.67($0.79) per share-13.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$26.80B$8.6525.5617.572.2021.83%32.60%13.29%7/15/2026 (Estimated)NVAXNovavax$440.30M$2.41N/AN/AN/A-14.73%-17.64%1.18%N/ALatest NVAX and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026NVAXNovavax-$0.25-$0.06+$0.19-$0.06$79.81 million$118.90 million4/14/2026Q1 2026JNJJohnson & Johnson$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion2/26/2026Q4 2025NVAXNovavax-$0.66$0.11+$0.77$0.11$90.26 million$136.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.202.35%+5.25%60.12%64 YearsNVAXNovavaxN/AN/AN/AN/AN/ALatest NVAX and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/14/2026JNJJohnson & Johnsonquarterly$1.342.23%5/26/20265/26/20266/9/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.461.030.77NVAXNovavaxN/A2.132.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableNVAXNovavax1,990164.43 million162.78 millionOptionableNVAX and JNJ HeadlinesRecent News About These CompaniesTraders Buy High Volume of Call Options on Novavax (NASDAQ:NVAX)1 hour ago | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Receives Consensus Rating of "Hold" from AnalystsMay 8 at 2:43 AM | marketbeat.comNVAX stock eyes breakout week: Novavax claims patients were ‘twice as likely’ to pick its COVID shot over Moderna againMay 7 at 6:06 PM | msn.comNovavax to Participate in BofA Securities 2026 Health Care ConferenceMay 7 at 6:06 PM | finance.yahoo.comNovavax to Participate in BofA Securities 2026 Health Care ConferenceMay 7 at 4:00 PM | prnewswire.comCompany News for May 7, 2026May 7 at 1:05 PM | finance.yahoo.comNVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal MomentumMay 7 at 1:05 PM | finance.yahoo.comNVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal MomentumMay 7 at 12:16 PM | zacks.comNovavax (NASDAQ:NVAX) Given New $9.00 Price Target at TD CowenMay 7 at 4:25 AM | americanbankingnews.comNovavax (NVAX) Q3 2025 Earnings TranscriptMay 7 at 1:14 AM | fool.comNovavax (NASDAQ:NVAX) Issues Quarterly Earnings ResultsMay 6 at 11:36 PM | marketbeat.comNovavax Earnings Call: Partnerships, Cash Runway and Profit PathMay 6 at 9:11 PM | tipranks.comNovavax (NVAX) Q2 2025 Earnings TranscriptMay 6 at 8:14 PM | fool.comNovavax (NVAX) Q1 2026 Earnings TranscriptMay 6 at 8:14 PM | fool.comNovavax, Inc. Q1 2026 Earnings Call SummaryMay 6 at 8:14 PM | app.moby.coANovavax Q1 Earnings Call HighlightsMay 6 at 4:41 PM | marketbeat.comNovavax (NASDAQ:NVAX) Price Target Raised to $9.00 at TD CowenMay 6 at 4:06 PM | marketbeat.comWhy Novavax Stock Is Trading Higher On Wednesday?May 6 at 3:30 PM | benzinga.comNovavax rises after strong Q1 beat driven by Pfizer dealMay 6 at 3:12 PM | seekingalpha.comNovavax (NVAX) Reports Q1 Loss, Beats Revenue EstimatesMay 6 at 3:12 PM | finance.yahoo.comNovavax, Inc. (NVAX) Q1 2026 Earnings Call TranscriptMay 6 at 3:01 PM | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings ResultsBy Thomas Hughes | April 14, 2026NVAX and JNJ Company DescriptionsJohnson & Johnson NYSE:JNJ$221.06 -1.45 (-0.65%) As of 01:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novavax NASDAQ:NVAX$10.44 +1.21 (+13.12%) As of 01:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
